Piramal Pharma Limited (PPLPHARMA) Stock Statistics & Valuation Metrics

Piramal Pharma Limited has a market cap or net worth of ₹280.74B. The enterprise value is ₹330.96B.

Piramal Pharma Limited has 1,329,248,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Piramal Pharma Limited’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 5.90%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Piramal Pharma Limited had revenue of 91.51B and earned 911.30M in profits. Earnings per share was 0.69.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Piramal Pharma Limited pays an annual dividend of ₹0.14, resulting in a dividend yield of 0.06%

Piramal Pharma Limited upcoming earnings date is Jul 28, 2025, During Market Hours (Confirmed).

Piramal Pharma Limited as a current ratio of 1.54, with Debt / Equity ratio of 59.77%

In the past 12 months, Piramal Pharma Limited has paid 3.24B in taxes.

Piramal Pharma Limited EV to EBITDA ratio is 24.63, with an EV/FCF ratio of 151.72.

Piramal Pharma Limited has ₹5.21B in cash and marketable securities with ₹48.56B in debt, giving a net cash position of ₹43.35B billion.

Gross margin is 48.12%, with operating margin of 39.47%, and net profit margin of 1.00%.

The average price target for Piramal Pharma Limited is ₹287.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy